Total Payments
$12,462
2024 Payments
$392.79
Companies
11
Transactions
60
Medicare Patients
118
Medicare Billing
$37,112
Payment Breakdown by Category
Other$4,110 (33.0%)
Food & Beverage$2,915 (23.4%)
Travel$2,870 (23.0%)
Consulting$2,475 (19.9%)
Education$91.34 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $4,110 | 3 | 33.0% |
| Food and Beverage | $2,915 | 38 | 23.4% |
| Travel and Lodging | $2,870 | 15 | 23.0% |
| Consulting Fee | $2,475 | 1 | 19.9% |
| Education | $91.34 | 3 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Horizon Therapeutics plc | $3,960 | 2 | $0 (2020) |
| GENZYME CORPORATION | $3,187 | 28 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $2,735 | 4 | $0 (2019) |
| Travere Therapeutics, Inc. | $1,743 | 12 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $301.01 | 4 | $0 (2020) |
| Relypsa, Inc. | $244.47 | 3 | $0 (2017) |
| Takeda Pharmaceuticals U.S.A., Inc. | $129.83 | 2 | $0 (2024) |
| Novo Nordisk Inc | $97.29 | 1 | $0 (2017) |
| Novo Nordisk Health Care AG | $44.52 | 1 | $0 (2024) |
| Coloplast Corp | $17.33 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $392.79 | 4 | Travere Therapeutics, Inc. ($119.83) |
| 2023 | $1,800 | 14 | Travere Therapeutics, Inc. ($1,623) |
| 2020 | $4,110 | 3 | Horizon Therapeutics plc ($3,960) |
| 2019 | $3,942 | 15 | Mallinckrodt Enterprises LLC ($2,735) |
| 2018 | $746.23 | 6 | GENZYME CORPORATION ($746.23) |
| 2017 | $1,470 | 18 | GENZYME CORPORATION ($1,004) |
All Payment Transactions
60 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/06/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $119.83 | General |
| 10/26/2024 | Novo Nordisk Health Care AG | — | Food and Beverage | In-kind items and services | $44.52 | General |
| 08/13/2024 | GENZYME CORPORATION | FABRAZYME (Biological) | Food and Beverage | In-kind items and services | $119.43 | General |
| Category: Genetic Disease | ||||||
| 01/24/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $109.01 | General |
| Category: IMMUNOLOGY | ||||||
| 12/06/2023 | Travere Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $70.78 | General |
| 12/06/2023 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $35.66 | General |
| 11/16/2023 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $20.82 | General |
| Category: IMMUNOLOGY | ||||||
| 10/27/2023 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $71.76 | General |
| 10/27/2023 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $20.00 | General |
| 10/21/2023 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $74.96 | General |
| 10/21/2023 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $49.95 | General |
| 10/21/2023 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $39.96 | General |
| 10/20/2023 | Travere Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $470.60 | General |
| 10/20/2023 | Travere Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $441.35 | General |
| 10/20/2023 | Travere Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $192.71 | General |
| 10/20/2023 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $155.54 | General |
| 10/04/2023 | Coloplast Corp | SpeediCath (Device) | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: Continence Care | ||||||
| 07/27/2023 | GENZYME CORPORATION | FABRAZYME (Biological) | Food and Beverage | In-kind items and services | $138.69 | General |
| Category: Genetic Disease | ||||||
| 12/11/2020 | Horizon Therapeutics plc | PROCYSBI (Drug) | Honoraria | Cash or cash equivalent | $1,800.00 | General |
| Category: PROCYSBI | ||||||
| 09/15/2020 | Alexion Pharmaceuticals, Inc. | Ultomiris (Drug) | Honoraria | Cash or cash equivalent | $150.00 | General |
| Category: Immunology | ||||||
| 05/28/2020 | Horizon Therapeutics plc | PROCYSBI (Drug) | Honoraria | Cash or cash equivalent | $2,160.00 | General |
| Category: PROCYSBI | ||||||
| 12/13/2019 | Mallinckrodt Enterprises LLC | ACTHAR (Biological) | Education | In-kind items and services | $89.99 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
| 11/05/2019 | Mallinckrodt Enterprises LLC | ACTHAR (Biological) | Consulting Fee | Cash or cash equivalent | $2,475.00 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
| 10/22/2019 | Mallinckrodt Enterprises LLC | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $132.00 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
| 10/22/2019 | Mallinckrodt Enterprises LLC | ACTHAR (Biological) | Travel and Lodging | In-kind items and services | $38.30 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 14 | 111 | $26,418 | $10,313 |
| 2022 | 2 | 33 | 137 | $32,067 | $10,150 |
| 2021 | 2 | 35 | 123 | $28,724 | $8,656 |
| 2020 | 2 | 36 | 108 | $25,198 | $7,993 |
Total Patients
118
Total Services
479
Medicare Billing
$37,112
Procedure Codes
7
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 111 | $26,418 | $10,313 | 39.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 20 | 88 | $20,944 | $6,931 | 33.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 13 | 49 | $11,123 | $3,219 | 28.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 21 | 73 | $17,374 | $5,470 | 31.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 14 | 50 | $11,350 | $3,187 | 28.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 24 | 62 | $14,756 | $5,178 | 35.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 12 | 46 | $10,442 | $2,815 | 27.0% |
About Dr. Robert Gillespie, MD
Dr. Robert Gillespie, MD is a Pediatric Nephrology healthcare provider based in Fort Worth, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/29/2007. The National Provider Identifier (NPI) number assigned to this provider is 1912043738.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Gillespie, MD has received a total of $12,462 in payments from pharmaceutical and medical device companies, with $392.79 received in 2024. These payments were reported across 60 transactions from 11 companies. The most common payment nature is "Honoraria" ($4,110).
As a Medicare-enrolled provider, Gillespie has provided services to 118 Medicare beneficiaries, totaling 479 services with total Medicare billing of $37,112. Data is available for 4 years (2020–2023), covering 7 distinct procedure/service records.
Ad
Practice Information
- Specialty Pediatric Nephrology
- Location Fort Worth, TX
- Active Since 01/29/2007
- Last Updated 05/14/2021
- Taxonomy Code 2080P0210X
- Entity Type Individual
- NPI Number 1912043738
Products in Payments
- PROCYSBI (Drug) $3,960
- NO PRODUCT DISCUSSED (Drug) $2,929
- ACTHAR (Biological) $2,735
- FABRAZYME (Biological) $258.12
- Veltassa (Drug) $244.47
- Ultomiris (Drug) $150.00
- LIVTENCITY (Drug) $129.83
- SOLIRIS (Drug) $123.79
- Norditropin (Drug) $97.29
- SpeediCath (Device) $17.33
- (815) Thiola (Drug) $1.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.